Current Report Filing (8-k)
January 09 2017 - 8:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2017
ZOGENIX, INC.
(Exact
Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-34962
|
|
20-5300780
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
5858 Horton Street, #455, Emeryville, CA
|
|
94608
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(510) 550-8300
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 2.02 Results of Operations and Financial Condition.
On January 9, 2017, Zogenix, Inc. (the Company or Zogenix) announced that its preliminary unaudited cash and cash equivalents as
of December 31, 2016 were approximately $91.6 million.
The preliminary unaudited cash position discussed above is subject to the completion of
financial closing procedures and other developments that may arise between now and the time the financial results for the fourth quarter are finalized, as well as the completion of the audit of the 2016 financial statements. Therefore, actual
results may differ materially from these estimates. In addition, the above estimates do not present all information necessary for an understanding of Zogenixs financial condition as of December 31, 2016.
In accordance with General Instruction B.2 of Form
8-K,
the information in Item 2.02 of this Current Report on
Form
8-K
shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that
section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, whether made before or after the date hereof, except as expressly set forth
by specific reference in such filing to this Current Report on Form
8-K.
Item 7.01 Regulation FD Disclosure.
Beginning on January 9, 2017, representatives of Zogenix will be attending meetings with investors, analysts and other parties in connection with the
J.P. Morgan 34th Annual Healthcare Conference in San Francisco, California. During these meetings, Zogenix will present the slides attached as Exhibit 99.1 to this Current Report on Form
8-K,
which is
incorporated herein by reference.
The information in this Item 7.01, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall
not be deemed filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act, whether made
before or after the date hereof, except as expressly set forth by specific reference in such filing to this item of this report.
***
Zogenix cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. Words such as
believes, anticipates, plans, expects, indicates, will, intends, potential, suggests, assuming and similar expressions are
intended to identify forward-looking statements. These statements are based on the Companys current beliefs and expectations. These forward-looking statements include statements regarding Zogenixs cash position as of December 31,
2016, the potential commercialization of ZX008; the timing of
top-line
results from the Phase 3 clinical trial of ZX008 in Dravet syndrome and other 2017 milestones; and the timing of any submission of a new
drug application to the U.S. Food and Drug Administration or comparable market authorization filing in Europe. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved.
Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in Zogenixs business, including, without limitation: risks related to changes in estimated financial amounts based on the completion of
financial closing procedures and the audit of the financial statements, the uncertainties associated with the clinical development and regulatory approval of product candidates such as ZX008, including potential delays in the commencement,
enrollment and completion of clinical trials; the potential that earlier clinical trials and studies may not be predictive of future results; Zogenixs reliance on third parties to conduct its clinical trials, enroll patients, manufacture its
preclinical and clinical drug supplies and manufacture commercial supplies of its drug products, if approved; unexpected adverse side effects or inadequate therapeutic efficacy of ZX008 that could limit approval and/or commercialization, or that
could result in recalls or product liability claims; Zogenixs ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States, that apply to its
product development activities; Fast Track designation may not result in an expedited regulatory review process; the potential for distraction of management related to the transition of management responsibilities; and other risks described in
Zogenixs filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update
this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the
Private Securities Litigation Reform Act of 1995.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Slide Presentation
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ZOGENIX, INC.
|
|
|
|
|
Date: January 9, 2017
|
|
|
|
By:
|
|
/s/ Stephen J. Farr, Ph.D.
|
|
|
|
|
|
|
Name: Stephen J. Farr, Ph.D.
Title:
President and Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Slide Presentation
|
Zogenix (NASDAQ:ZGNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zogenix (NASDAQ:ZGNX)
Historical Stock Chart
From Sep 2023 to Sep 2024